Philippe Grandjean1,2, Clara Amalie Gade Timmermann2, Marie Kruse2, Flemming Nielsen2, Pernille Just Vinholt3, Lasse Boding4, Carsten Heilmann5, Kåre Mølbak4,6. 1. The Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America. 2. The Department of Public Health, University of Southern Denmark, Odense, Denmark. 3. The Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark. 4. The Department of Epidemiology, Statens Serum Institut, Copenhagen, Denmark. 5. Pediatric Clinic, Rigshospitalet - National University Hospital, Copenhagen, Denmark. 6. The Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute to an association with disease severity. METHODS: From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome. RESULTS: Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an unadjusted odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease. Among those hospitalized, the fully adjusted OR for getting into intensive care or expiring was 5.18 (1.29, 20.72) when based on plasma samples obtained at the time of diagnosis or up to one week before. CONCLUSIONS: Measures of individual exposures to immunotoxic PFASs included short-chain PFBA known to accumulate in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of a more severe course of COVID-19. Given the low background exposure levels in this study, the role of exposure to PFASs in COVID-19 needs to be ascertained in populations with elevated exposures.
BACKGROUND: The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute to an association with disease severity. METHODS: From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome. RESULTS: Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an unadjusted odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease. Among those hospitalized, the fully adjusted OR for getting into intensive care or expiring was 5.18 (1.29, 20.72) when based on plasma samples obtained at the time of diagnosis or up to one week before. CONCLUSIONS: Measures of individual exposures to immunotoxic PFASs included short-chain PFBA known to accumulate in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of a more severe course of COVID-19. Given the low background exposure levels in this study, the role of exposure to PFASs in COVID-19 needs to be ascertained in populations with elevated exposures.
Authors: Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Parisa Montazeri; Cathrine Thomsen; Maribel Casas; Jeroen de Bont; Line S Haug; Léa Maitre; Eleni Papadopoulou; Amrit K Sakhi; Rémy Slama; Pierre Jean Saulnier; Jose Urquiza; Regina Grazuleviciene; Sandra Andrusaityte; Rosie McEachan; John Wright; Leda Chatzi; Xavier Basagaña; Martine Vrijheid Journal: Int J Hyg Environ Health Date: 2019-04-19 Impact factor: 5.840
Authors: Elizabeth J Williamson; Alex J Walker; Krishnan Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Y S Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen J W Evans; Liam Smeeth; Ben Goldacre Journal: Nature Date: 2020-07-08 Impact factor: 49.962
Authors: Sara Y Tartof; Lei Qian; Vennis Hong; Rong Wei; Ron F Nadjafi; Heidi Fischer; Zhuoxin Li; Sally F Shaw; Susan L Caparosa; Claudia L Nau; Tanmai Saxena; Gunter K Rieg; Bradley K Ackerson; Adam L Sharp; Jacek Skarbinski; Tej K Naik; Sameer B Murali Journal: Ann Intern Med Date: 2020-08-12 Impact factor: 25.391
Authors: Swati D G Rayasam; Max T Aung; Courtney Cooper; Carol Kwiatkowski; Dori R Germolec; Andrew A Rooney; Vickie R Walker; Chanese Forte; Tracey J Woodruff; Nicholas Chartres Journal: Environ Int Date: 2022-04-08 Impact factor: 13.352
Authors: Yun Liu; Melissa N Eliot; George D Papandonatos; Karl T Kelsey; Ruby Fore; Scott Langevin; Jessie Buckley; Aimin Chen; Bruce P Lanphear; Kim M Cecil; Kimberly Yolton; Marie-France Hivert; Sharon K Sagiv; Andrea A Baccarelli; Emily Oken; Joseph M Braun Journal: Environ Health Perspect Date: 2022-03-10 Impact factor: 11.035
Authors: Alissa Cordner; Gretta Goldenman; Linda S Birnbaum; Phil Brown; Mark F Miller; Rosie Mueller; Sharyle Patton; Derrick H Salvatore; Leonardo Trasande Journal: Environ Sci Technol Date: 2021-07-07 Impact factor: 9.028
Authors: Dolores Catelan; Annibale Biggeri; Francesca Russo; Dario Gregori; Gisella Pitter; Filippo Da Re; Tony Fletcher; Cristina Canova Journal: Int J Environ Res Public Health Date: 2021-03-08 Impact factor: 3.390